Madrigal Pharmaceuticals Management
Management criteria checks 1/4
Madrigal Pharmaceuticals' CEO is Bill Sibold, appointed in Sep 2023, has a tenure of 1.17 years. total yearly compensation is $32.87M, comprised of 0.8% salary and 99.2% bonuses, including company stock and options. directly owns 0.028% of the company’s shares, worth $1.93M. The average tenure of the management team and the board of directors is 0.9 years and 8.3 years respectively.
Key information
Bill Sibold
Chief executive officer
US$32.9m
Total compensation
| CEO salary percentage | 0.8% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.03% |
| Management average tenure | less than a year |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$519m |
| Jun 30 2024 | n/a | n/a | -US$510m |
| Mar 31 2024 | n/a | n/a | -US$444m |
| Dec 31 2023 | US$33m | US$275k | -US$374m |
Compensation vs Market: Bill's total compensation ($USD32.87M) is above average for companies of similar size in the US market ($USD7.97M).
Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.
CEO
Bill Sibold (58 yo)
1.2yrs
Tenure
US$32,871,801
Compensation
Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.2yrs | US$32.87m | 0.028% $ 1.9m | |
| Founder | 13.2yrs | US$6.93m | 5% $ 342.4m | |
| Chief Commercial Officer | less than a year | US$3.14m | no data | |
| CFO & Senior VP | less than a year | no data | no data | |
| Senior Vice President of Business Planning & Operations | less than a year | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Chief Investor Relations Officer | less than a year | no data | no data | |
| Chief Compliance Office & General Counsel | less than a year | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical & Technical Operations | no data | no data | no data | |
| Senior Vice President of Clinical Management | no data | no data | no data | |
| Chief Pharmaceutical Development Officer | 3.3yrs | no data | 0.025% $ 1.7m |
0.9yrs
Average Tenure
60yo
Average Age
Experienced Management: MDGL's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.2yrs | US$32.87m | 0.028% $ 1.9m | |
| Founder | 8.3yrs | US$6.93m | 5% $ 342.4m | |
| Independent Lead Director | 8.3yrs | US$65.00k | 1.7% $ 116.4m | |
| Independent Director | 8.3yrs | US$77.50k | 0.0055% $ 376.2k | |
| Independent Chairman of the Board | 1.4yrs | US$33.75k | 0.011% $ 753.1k | |
| Director | 8.3yrs | US$9.80m | 4.35% $ 298.0m | |
| Independent Director | 8.3yrs | US$62.50k | 0.047% $ 3.2m | |
| Independent Director | 5.4yrs | US$57.50k | 0.0055% $ 376.2k | |
| Independent Director | 1.4yrs | US$27.50k | 0.011% $ 753.1k |
8.3yrs
Average Tenure
66yo
Average Age
Experienced Board: MDGL's board of directors are considered experienced (8.3 years average tenure).